Sang Y Kang

Array ( [id] => 16581539 [patent_doc_number] => 20210015941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/933845 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16800226 [patent_doc_number] => 10995147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Preparations and methods for treating a GD2 positive cancer [patent_app_type] => utility [patent_app_number] => 16/920880 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 19960 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16920880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389626 [patent_doc_number] => 20200330567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => Radiohalogenated Agents for in Situ Immune Modulated Cancer Vaccination [patent_app_type] => utility [patent_app_number] => 16/919191 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375115 [patent_doc_number] => 20200323957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/918527 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733561 [patent_doc_number] => 11802284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Medicine for treating cancer and method for treating cancer [patent_app_type] => utility [patent_app_number] => 16/918520 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 9326 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375139 [patent_doc_number] => 20200323981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor [patent_app_type] => utility [patent_app_number] => 16/946585 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389680 [patent_doc_number] => 20200330621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination [patent_app_type] => utility [patent_app_number] => 16/914563 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16914563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236660 [patent_doc_number] => 11180532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/915354 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 37137 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 251 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16998421 [patent_doc_number] => 11077203 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-SEZ6 antibody drug conjugates and methods of use [patent_app_type] => utility [patent_app_number] => 16/908645 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 16852 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16763520 [patent_doc_number] => 20210109101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients [patent_app_type] => utility [patent_app_number] => 16/884737 [patent_app_country] => US [patent_app_date] => 2020-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368163 [patent_doc_number] => 11648311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Cancer treatments [patent_app_type] => utility [patent_app_number] => 16/872840 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 68 [patent_no_of_words] => 19099 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18383429 [patent_doc_number] => 11654193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Cancer treatment combinations [patent_app_type] => utility [patent_app_number] => 16/870803 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 63 [patent_no_of_words] => 43806 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16870803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16345116 [patent_doc_number] => 20200309766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => CHEMOPREDICTIVE ASSAY FOR RECURRENT CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/835220 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17996701 [patent_doc_number] => 11497787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Functionalized poly-ADP-ribose polymers for drug delivery [patent_app_type] => utility [patent_app_number] => 17/599309 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 10 [patent_no_of_words] => 16662 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359298 [patent_doc_number] => 20200316049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS [patent_app_type] => utility [patent_app_number] => 16/828895 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359295 [patent_doc_number] => 20200316046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => NANOPARTICLE COMPOSITIONS OF ENDOTHELIN B RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/828900 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267342 [patent_doc_number] => 20200268829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING METASTASES OF AN ENDOTHELIN B RECEPTOR EXPRESSING CANCER [patent_app_type] => utility [patent_app_number] => 16/828911 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310757 [patent_doc_number] => 20200289495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => METHODS OF INHIBITING ENDOTHELIN B RECEPTOR EXPRESSING TUMOR METASTASES [patent_app_type] => utility [patent_app_number] => 16/828907 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243527 [patent_doc_number] => 20210363270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG [patent_app_type] => utility [patent_app_number] => 17/052952 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090519 [patent_doc_number] => 20200199246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ANTI-CD276 ANTIBODIES (B7H3) [patent_app_type] => utility [patent_app_number] => 16/812980 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16812980 [rel_patent_id] =>[rel_patent_doc_number] =>)